UnitedHealth's stock has fallen 46.5% over the past year, raising its dividend yield to about 2.8%, making it a candidate for the Dogs of the Dow contrarian income strategy. Despite recent price declines, the company expects earnings growth and strong cash flow in 2026, with management actively buying shares, signaling confidence in a recovery. Risks include high medical care costs, declining membership, and legal challenges, but Wall Street analysts mostly rate the stock as a Buy with a consensus price target above current levels. Investors following the Dogs strategy see UnitedHealth as a potential rebound play backed by solid dividends and improving fundamentals.
Piper Sandler raised its price target for UnitedHealth Group to $475, suggesting a 13.3% upside from its current price of $419.23. The company, the largest U.S. health insurer, has consistently beaten earnings estimates, with its latest EPS of $7.23 ...
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
Elevance Health and UnitedHealth Group, two of the largest U.S. health insurers, are set to report their second-quarter earnings this week. Investors and analysts are watching closely to see if these companies have maintained control over rising medi...
